UBS Initiates Coverage On Versigent with Buy Rating, Announces Price Target of $43

Benzinga Newsdesk www.benzinga.com Neutral 50.6%

Neg 0% Neu 50.6% Pos 0%

UBS analyst Joseph Spak initiates coverage on Versigent (NYSE:VGNT) with a Buy rating and announces Price Target of $43.